To see whether signatures indicative of these favorable responses could be identified at the resolution of paracrine interactions in advance of PD1 therapy, we evaluated TIL expression of PD1 and tumor cell expression of PDL1 in TCCNs. This evidence concerns the gene CD274 and neoplasm.